Abstract
Statins can inhibit growth of malignant cells. Aims: The aim of the present work was to increase efficacy of simvastatin on chronic meyloid leukemia K562 cells by folate targeted solid lipid nanoparticles (SLN). Methodology: Folate targeting agent was prepared by chemical reaction between folic acid and dodecylamine. Folate targeted SLNs of simvastatin were prepared by an emulsification- solvent evaporation method. Then cytotoxicity of SLNs was studied on K562 cell line by Trypan blue and cellular uptake by flow cytometry method. Different concentrations of doxorubicin were used in combination to SLNs of simvastatin to study their possible synergistic effect in reducing the required cytotoxic dose of doxorubicin. Results: Simvastatin loaded SLNs were more cytotoxic than free simvastatin. The targeting property of glyceryl monostearate (GMS) SLNs was more efficient than other studied lipids. SLNs of simvastatin could reduce the cytotoxic dose of doxorubicin particularly when the dose of doxorubicin was low. Conclusion: Folate targeted SLNs can significantly enhance cytotoxic effect of simvastatin on K562 cell line and show synergistic effect with doxorubicin in reducing its dose. This may be of great value from clinical point of view in reduction of the cardiac toxicity of doxorubicin.
Keywords: Chronic meyloid leukemia, cytotoxicity, folate targeting, K562 cell line, simvastatin, solid lipid nanoparticles
Current Nanoscience
Title:Folate Targeted Solid Lipid Nanoparticles of Simvastatin for Enhanced Cytotoxic Effects of Doxorubicin in Chronic Myeloid Leukemia
Volume: 8 Issue: 2
Author(s): J. Varshosaz, F. Hassanzadeh, H. Sadeghi and M. Shakery
Affiliation:
Keywords: Chronic meyloid leukemia, cytotoxicity, folate targeting, K562 cell line, simvastatin, solid lipid nanoparticles
Abstract: Statins can inhibit growth of malignant cells. Aims: The aim of the present work was to increase efficacy of simvastatin on chronic meyloid leukemia K562 cells by folate targeted solid lipid nanoparticles (SLN). Methodology: Folate targeting agent was prepared by chemical reaction between folic acid and dodecylamine. Folate targeted SLNs of simvastatin were prepared by an emulsification- solvent evaporation method. Then cytotoxicity of SLNs was studied on K562 cell line by Trypan blue and cellular uptake by flow cytometry method. Different concentrations of doxorubicin were used in combination to SLNs of simvastatin to study their possible synergistic effect in reducing the required cytotoxic dose of doxorubicin. Results: Simvastatin loaded SLNs were more cytotoxic than free simvastatin. The targeting property of glyceryl monostearate (GMS) SLNs was more efficient than other studied lipids. SLNs of simvastatin could reduce the cytotoxic dose of doxorubicin particularly when the dose of doxorubicin was low. Conclusion: Folate targeted SLNs can significantly enhance cytotoxic effect of simvastatin on K562 cell line and show synergistic effect with doxorubicin in reducing its dose. This may be of great value from clinical point of view in reduction of the cardiac toxicity of doxorubicin.
Export Options
About this article
Cite this article as:
Varshosaz J., Hassanzadeh F., Sadeghi H. and Shakery M., Folate Targeted Solid Lipid Nanoparticles of Simvastatin for Enhanced Cytotoxic Effects of Doxorubicin in Chronic Myeloid Leukemia, Current Nanoscience 2012; 8 (2) . https://dx.doi.org/10.2174/157341312800167542
DOI https://dx.doi.org/10.2174/157341312800167542 |
Print ISSN 1573-4137 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6786 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Cytotoxic and Mechanistic Effects of Aaptamine on Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Nanoplatforms for Delivery of siRNA to the Eye
Current Pharmaceutical Design The Urokinase Receptor as a Potential Target in Cancer Therapy
Current Pharmaceutical Design Hydrophobic Modification of Copper Nanospheres for Incorporation into Poloxamer Micelles, Aggregated Micellar Nanocages and Supramolecular Assemblies
Current Nanomedicine Oncolytic Viruses: The Best is Yet to Come
Current Cancer Drug Targets Boron Containing Macromolecules and Nanovehicles as Delivery Agents for Neutron Capture Therapy†
Anti-Cancer Agents in Medicinal Chemistry Tapasin and Human Leukocyte Antigen Class I Dysregulation Correlates with Survival in Glioblastoma Multiforme
Anti-Cancer Agents in Medicinal Chemistry Anti-Angiogenesis and RGD-Containing Snake Venom Disintegrins
Current Pharmaceutical Design Cellomics as Integrative Omics for Cancer
Current Proteomics Immunostimulatory Oligonucleotides
Recent Patents on Inflammation & Allergy Drug Discovery Treatment of Diffuse-Type Gastric Cancer Cells Using 213Bi-Radioimmunoconjugates In Vitro and In Vivo Following Intraperitoneal Dissemination
Current Radiopharmaceuticals Human ABC Transporters at blood-CNS Interfaces as Determinants of CNS Drug Penetration
Current Pharmaceutical Design Surface Modification of Nanocarriers for Cancer Therapy
Current Nanoscience Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Blood-Brain Barrier Penetration and Drug Development from an Industrial Point of View
Current Medicinal Chemistry - Central Nervous System Agents Proteomic Analysis of Mitochondrial Proteins on the Mechanism of Apoptotic Under Amorphophallus konjac Tuber (KONJAC) Extracts in Gas tric Cancer Cell
Current Proteomics Peptide Targeted Copper-64 Radiopharmaceuticals
Current Topics in Medicinal Chemistry Role of the Renin-Angiotensin System in Gynecologic Cancers
Current Cancer Drug Targets Pathobiology and Therapeutic Implications of Tumor Acidosis
Current Medicinal Chemistry Accessing the Blood-Brain Barrier to Treat Brain Disorders
Current Nanomedicine